Targeting ‘Persister’ Cancer cells with DFFB Inhibition shows promise
Table of Contents
Researchers have identified a protein, DNA fragmentation factor B (DFFB), that plays a crucial role in the regrowth of “persister” cancer cells – those that survive initial treatment and drive cancer recurrence. This discovery, published in Nature Cell Biology, suggests that inhibiting DFFB could considerably improve cancer treatment outcomes, especially when combined with existing therapies. The research focused on melanoma, lung, and breast cancers, but the findings may have broader implications for other cancer types.
Understanding Cancer Persister Cells
Cancer treatment frequently enough initially reduces tumor size,but the disease frequently returns due to the survival and regrowth of persister cells. These cells are not necessarily resistant to the drugs used; instead, they enter a dormant state and survive treatment, only to become active again later. Understanding how these cells persist and reactivate is critical for developing more effective long-term cancer therapies.
The Role of DFFB in Cancer Cell Persistence
The study revealed that persister cells exhibit ongoing, low-level activation of DFFB, a protein normally involved in programmed cell death (apoptosis) by breaking down DNA. Though, the level of activation isn’t high enough to kill the cells. Instead, it disrupts the signaling pathways that normally regulate cell growth. This disruption allows the persister cells to evade the signals that would otherwise keep them dormant.
How DFFB Impacts Growth Signals
Specifically, DFFB activation interferes with the cells’ ability to respond to signals that control their growth. By subtly altering cellular processes, DFFB creates a permissive environment for regrowth once the initial treatment ends. Researchers found that removing DFFB prevented persister cancer cells from regrowing during drug treatment, keeping them in a dormant state.
DFFB as a Therapeutic Target
Importantly, DFFB is not essential for normal cell function, making it an attractive target for cancer therapies.The research indicates that inhibiting DFFB could prevent persister cells from reactivating, perhaps prolonging the effectiveness of targeted treatments. This suggests a promising avenue for developing combination therapies.
Study Details and Funding
the findings were published in Nature Cell Biology. The research was supported by grants from the department of Defense, the National Institutes of Health, and the American Cancer Society. Dr. Hangauer, a researcher involved in the study, has financial ties to BridgeBio subsidiary Ferro Therapeutics as a cofounder, consultant, and research funding recipient.
Key Takeaways
- Persister cancer cells survive treatment and drive recurrence.
- DFFB protein activation, even at low levels, disrupts growth control in persister cells.
- Removing DFFB keeps persister cells dormant.
- DFFB is a promising target for combination cancer therapies.
This research offers a new perspective on tackling cancer recurrence by targeting the mechanisms that allow persister cells to survive and regrow. Further studies are needed to develop and test DFFB inhibitors, but these findings represent a notable step towards more durable cancer treatments and improved patient outcomes.